Objectives & Accreditation
ACTIVITY FORMAT Live
TARGET AUDIENCE This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.
TYPE OF ACTIVITY Live Activity; Knowledge
EDUCATIONAL OBJECTIVES At the conclusion of this activity, all participants should be able to:
Session I: Lipids Across the Lifetime Discuss the current ASCVD-risk screening recommendations and guidelines as they relate to all age groups; Identify lipid-lowering therapeutic approaches for older adults;
Sessions II: Lp(a)
Evaluate the application of lipid and non-lipid biomarkers in cardiovascular risk detection; Outline current and emerging pharmacologic therapies for patients with elevated levels of lipoprotein a;
Sessions III: Difficult patient cases
Review representative clinical cases in the management of patients with dyslipidemia;
Sessions IV: Autoimmune Disorders
Identify appropriate dyslipidemia management strategies in patients with rheumatic disorders and HIV;
Sessions V: Unusual Lipid Disorders
Describe the mechanisms and manifestations of unusual genetic lipid disorders, including Familial Chylomicronemia Syndrome, Lipodystrophy, and Familial Combined Hyperlipidemia; Identify effective treatment strategies for patients with unusual lipid disorders;
Session VI: Treatment of Diabetes- Role of Lipidologist in Treatment of Type 1 & 2 Diabetes
Identify combination therapies for the management of type 2 diabetes; Describe the pros and cons of bariatric surgery for the treatment of obesity;
Session VII: Approaches to Care
Review management options for drug-drug interactions in patients using combination therapies; Identify specialized lipid management strategies for patients with a history of transplantation.
At the conclusion of this activity, all participants should be able to:
Discuss strategies to improve the knowledge, skills or performance of the healthcare team.
CRITERIA FOR SUCCESS Statements of credit will be awarded based on the participant’s attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. If you have questions about this CME/CE activity, please contact the NLA at [email protected]. Please claim credit by March 24, 2017.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks. COMMERCIAL SUPPORT This activity is supported by educational grants from Aegerion, Inc, Akcea Therapeutics, A Subsidiary of Ionis Pharmaceuticals, Inc. and Amgen.
CREDIT DESIGNATION
CME credit provided by the National Lipid Association In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and The Postgraduate Institute for Medicine. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The National Lipid Association designates this live activity for a maximum of 13.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
Physician Assistants NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
Dietitians The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 13 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.
CE Credit provided by Postgraduate Institute for Medicine
Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Session I- Universal Activity Number 0809-9999-17-094-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 2.00 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education
Session II- Universal Activity Number 0809-9999-17-095-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education
Session III- Universal Activity Number 0809-9999-17-096-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 2.25 contact hour(s) (.225 CEUs) of the Accreditation Council for Pharmacy Education
Session IV – Universal Activity Number 0809-9999-17-097-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 2.00 contact hour(s) (.2 CEUs) of the Accreditation Council for Pharmacy Education
Session V– Universal Activity Number 0809-9999-17-098-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 2.00 contact hour(s) (.2 CEUs) of the Accreditation Council for Pharmacy Education Session VI – Universal Activity Number 0809-9999-17-099-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 2.00 contact hour(s) (.2 CEUs) of the Accreditation Council for Pharmacy Education
Session VII – Universal Activity Number 0809-9999-17-108-L01-P (Knowledge) Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125 CEUs) of the Accreditation Council for Pharmacy Education
Nursing This educational activity for 12.6 contact hours is provided by the Postgraduate Institute for Medicine. Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Session I- 2.0 credits; Session II- 1.3; Session III- 2.1 credits; Session IV- 2.0 credits; Session V- 2.0 credits; Session VI- 2.0 credits; Session VII- 1.2.
Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
Faculty and Planners
Benjamin J. Ansell, MD, FNLA Advisory Board- Amgen Consultant- Amgen Ownership Interest- Bruin Pharma Speaker- Amgen Stock- Biogen, Merck & Co., Inc., Regeneron
Karen E. Aspry, MD, MS, FNLA Contracted Research- Amgen, Ionis
Christie M. Ballantyne, MD, FNLA Consultant- Abbott Diagnostic, Amarin, Amgen, AstraZeneca, Eli Lilly, Esperion Therapeutics, Genzyme, Matinas BioPharma Inc., Merck & Co., Inc., Novartis, Pfizer, Regeneron, Roche, Sanofi-Synthelabo Contracted Research- Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion Therapeutics, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Sythelabo, Takeda
Harold E. Bays, MD, FNLA Consultant- Akcea, Alnylam Pharmaceuticals, Amgen, Eli Lilly, Esperion Therapeutics, Ionis, Janssen, Johnson & Johnson, Merck & Co., Inc., Moderna, Novartis, Procter & Gamble, Regeneron, Sanofi, Takeda, Teva Contracted Research- Alere, Allergan, Amarin, Amgen, Arisaph, AstraZeneca, Bristol-Myers Squibb, Catabasis, Cymabay, Dr. Reddy, Eisai, Elcelyx, Eli Lilly, Esperion Therapeutics, Ferrer/ Chiltern, Gemphire, Gilead, GlaxoSmithKline, Janssen, Johnson & Johnson, Kowa, Merck & Co., Inc., Nektar, Nichi-Iko, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, Selecta, Takeda, TIMI Speaker- Amarin, Amgen, AstraZeneca, Eisai, Regeneron, Sanofi, Takeda
Eliot A. Brinton, MD, FNLA Consultant- Alexion Pharmaceuticals, Amarin, Amgen, Aralez, Kastle, Kowa, Merck & Co., Inc., PTS Diagnostics, Regeneron, Sanofi- Aventis US Speaker- Alexion Pharmaceuticals, Amarin, Amgen, Janssen Pharmaceuticals, Inc., Kastle, Kowa, Merck & Co., Inc., Regeneron, Sanofi- Aventis US Steering Committee- Amarin, Kowa
Clay A. Cauthen, MD, MA Speaker- Novartis
Dave Dixon, PharmD, CLS, FNLA, AACC Has nothing to disclose.
P. Barton Duell, MD, FNLA Consultant- Akcea, Amgen, Esperion Therapeutics, Kaneka Pharma America, LLC, Kastle, Regeneron, Retrophin, Inc. Contracted Research- Amgen, Esperion Therapeutics, Kaneka Pharma America, LLC, Regeneron, Retrophin, Inc. Speaker- Merck & Co., Inc., Sanofi
Daniel A. Duprez, MD, PhD, FNLA Consultant- Amgen Contracted Research- AstraZeneca, Pfizer, Regeneron Speaking- Amgen
Sergio Fazio, MD, PhD, FNLA Advisory Board- Aegerion Pharmaceuticals, Amarin, Amgen, Kowa, Merck & Co., Inc., Sanofi Consultant- Aegerion Pharmaceuticals, Amarin, Amgen, Kowa, Merck & Co., Inc., Sanofi
Anne C. Goldberg, MD, FACP, FNLA Contracted Research- Amarin, Amgen, Genzyme/ ISIS Pharmaceuticals, IONIS, Merck & Co., Inc., Pfizer, Regeneron, Regeneron/ sanofi-aventis Consultant- OptumRX , Sanofi/ Regeneron Scholarly Contributions- Merck & Co., Inc.
Antonio M. Gotto, Jr., MD, DPhil, FNLA Advisory Board- Vatera Capital Board of Directors- Aegerion Pharmaceuticals, Arisaph Pharmaceuticals, Esperion Therapeutics Consultant- Kowa, Merck & Co., Inc., Pfizer Data Safety Monitoring Board- Isis
Robert Greenfield, MD, FNLA Speaker- Amgen, Regeneron, Sanofi
Yehuda Handelsman, MD, FNLA Associate Editor- Journal of Diabetes Consultant- Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer- Ingelheim, GlaxoSmithKline, Janssen, Merck & Co., Inc., Novo Nordisk, Regeneron, Sanofi Contracted Research- Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer- Ingelheim, Esperion Therapeutics, Grifols USA, GlaxoSmithKline, Hanmi Pharmaceuticals, Intarcia Therapeutics, Inc., Lexicon, Merck & Co., Inc., Novo Nordisk, Sanofi Speaker- Amarin, Amgen, AstraZeneca, Boehringer- Ingelheim/ Lilly, Janssen, Novo Nordisk, Regeneron, Sanofi
Sean P. Heffron, MD, MS, MSc Has nothing to disclose.
Elizabeth Jackson, MSN, ACNS- BS, CLS, FNLA Advisory Board- sanofi-aventis u.s. and Regeneron Pharmaceuticals Speakers Bureau- sanofi-aventis u.s. and Regeneron Pharmaceuticals
Wahida Karmally, DrPH, RD, CDE, CLS, FNLA Has nothing to disclose.
Carol Kirkpatrick, PhD, RDN, MPH, CLS, FNLA Has nothing to disclose.
Gay J. Meyers, PA-C, CLS Has nothing to disclose.
Patrick M. Moriarty, MD, FNLA Advisory Board- Aegerion Pharmaceuticals, Eliaz Therapeutics, Ionis Consultant- Alexion Pharmaceuticals, Duke, Esperion Therapeutics, Lilly, Sanofi Contracted Research- Amgen, Catabasis, Genzyme, Ionis, Kaneka, Novartis, Pfizer, Regeneron, Sanofi Speaker- Alexion Pharmaceuticals, Amgen, Kowa, Regeneron Speakers Bureau- Aegerion Pharmaceuticals, Genzyme, Sanofi
Jennifer G. Robinson, MD, MPH, FNLA Consultant- Akcea/ Ionis, Amgen, Eli Lilly, Esperion Therapeutics, Merck & Co., Inc., Pfizer, sanofi-aventis u.s. and Regeneron Pharmaceuticals Contracted Research- Amarin, Amgen, AstraZeneca, Eli Lilly, Eisai Inc., GlaxoSmithKline, Merck & Co., Inc., Pfizer, sanofi-aventis u.s. and Regeneron Pharmaceuticals, Takeda
Joyce L. Ross, MSN, ANP, CRNP, FPCNA, CLS, FNLA Advisory Board- Amarin Consultant- Genzyme Speakers Bureau- Amarin, Amgen, AstraZeneca, Practice Point, sanofi-aventis Speaker- Abbott Laboratories, Kowa Pharmaceuticals
Joseph J, Saseen, PharmD, CLS, FNLA Has nothing to disclose.
Arthur Schwartzbard, MD Has nothing to disclose.
Michael D. Shapiro, DO, FNLA Advisory Board- Alexion Pharmaceuticals, Amgen, Bracco Diagnostics Inc. Consultant- Alexion Pharmaceuticals, GE Health Care, Synta Pharmaceuticals
James A. Underberg, MD, MS, FNLA Advisory Board- Akcea, Alexion Pharmaceuticals, Amgen, AstraZeneca, Gemphire Pharma., New Haven Pharmaceuticals, Regeneron, Sanofi Consultant- Aegerion Pharmaceuticals, Amarin, Amgen, Kinder Pharma, Recombine Contracted Research- Aegerion Pharmaceuticals, Pfizer Speaker- Alexion Pharmaceuticals, Amgen, AstraZeneca, Merck & Co., Inc., New Haven Pharmaceuticals, Regeneron, Sanofi Steering Committee- Aegerion Pharmaceuticals
Don P. Wilson, MD, FNLA Advisory Board- Aegerion Pharmaceuticals, Alexion Pharmaceuticals Contracted Research- Merck & Co., Inc., Novo Nordisk Speaker- Alexion Pharmaceuticals, Insulet Corp, Osler Institute
Kathleen L. Wyne, MD, PhD, FNLA Consultant- Abbvie, Akcea
Staff Disclosures
NLA Staff Has nothing to disclose.
Postgraduate Institute for Medicine The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker- Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
NLA CME Committee Reviewers
Christie M. Ballantyne, MD, FNLA Consultant- Abbott Diagnositc, Amarin, Amgen, AstraZeneca, Eli Lilly, Esperion, Genzyme, Matinas BioPharma Inc., Merck & Co., Inc., Novartis, Pfizer, Regeneron, Roche, Sanofi-Synthelabo Contracted Research- Abbott Diagnosic, Amarin, Amgen, Eli Lilly, Esperion, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Sythelabo, Takeda B Alan Bottenberg, DO, FACOI, FNLA Speakers Bureau- Amgen
Kathleen Hawke Byrne, CRNP, BSN, MSN Has nothing to disclose.
Manisha Chandalia, MD, FNLA Speaker- Amgen, AstraZeneca, Lilly, Merck & Co., Inc., Novo Nordisk, Regeneron, Sanofi
Dave Dixon, PharmD, CLS, FNLA, AACC Has nothing to disclose.
Abimbola O. Farinde, PharmD Has nothing to disclose.
Edward Mark Goldenberg, MD, FNLA Speaker- Amgen, Merck & Co., Inc., Regeneron
Eric K. Gupta, PharmD, BCPS, CLS, FCPhA, FNLA Advisory Board- Amarin
Mahmoud Adeeb Ahmad Hamdan, MD, CDE Has nothing to disclose.
Linda C. Hemphill, MD, FNLA Advisory Board- Aegerion Pharmaceuticals, Regeneron Contracted Research- Ionis, Regeneron, Sanofi-Aventis
Donald G Lamprecht, PharmD, BCPS, CLS, FNLA Has nothing to disclose.
Pamela B. Morris, MD, FACC, FACP, FACPM, FAHA, FNLA Advisory Board- Aegerion Pharmaceuticals, AstraZeneca, Regeneron/ sanofi-aventis
Saleem Naina, PharmD Has nothing to disclose.
Connie B. Newman, MD, FACP, FAMWA Has nothing to disclose.
Roda Plakogiannis, PharmD, BS, BCPS, CLS, FNLA Has nothing to disclose.
Michael D. Shapiro, DO, FACC, FSCCT, FNLA Advisory Board- Alexion Pharmaceuticals, Amgen, Bracco Diagnostics Inc. Consultant- Alexion Pharmaceuticals, GE Health Care, Synta Pharmaceuticals
Khalid Hasan Sheikh, MD, FNLA Speakers Bureau- Amarin, Amgen, Boehringer Ingelheim, Novartis
Scott W. Shurmur, MD, FNLA Speaker- Regeneron
Sean D. Stewart, PharmD, CLS, FNLA Has nothing to disclose. Wayne S. Warren, MD, FNLA Advisory Board- Amgen Speaker- Amarin, Amgen, Merck & Co., Inc.
Thomas Rhyne White, MD, FNLA Speaking- Amarin, Janssen Stocks- Amarin, ISIS Pharmaceuticals
Suzana D. Zamecnik, NP, CLS Has nothing to disclose.
DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCT This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLOSURE DECLARATION It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.
DISCLAIMER This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.